A phase II trial of 13-Cis retinoic acid [isotretinoin], alpha interferon, Taxotere [docetaxel], and estramustine for the treatment of hormone refractory prostate cancer.

Trial Profile

A phase II trial of 13-Cis retinoic acid [isotretinoin], alpha interferon, Taxotere [docetaxel], and estramustine for the treatment of hormone refractory prostate cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Docetaxel (Primary) ; Estramustine (Primary) ; Interferon alpha-2b (Primary) ; Isotretinoin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 17 Nov 2009 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov
    • 17 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top